US Incidence Rates of Herpes Zoster and Postherpetic Neuralgia From 1994 to 2018
Researchers’ findings on the incidence rate of herpes zoster among unvaccinated age groups informs new set of recommendations.
Sexually Transmitted Infections
Caution Required When Using Supplementary Nucleic Acid Amplification Tests for Gonorrhea
Research results highlighted the need for continued supplemental NAATs for oropharyngeal samples being tested for Nisseria gonorrhoeae.
USPSTF Urges Behavioral Counseling to Prevent STIs
The U.S. Preventive Services Task Force (USPSTF) recommends behavioral counseling interventions for preventing sexually transmitted infections.
Study Findings Support Use of Secnidazole for Trichomoniasis
Data from the pivotal phase 3 trial demonstrated clinically and statistically significant microbiological cure compared with placebo at the test of cure visit.
Serine 91 Genotype of gyrA Gonorrhea Successfully Treated With Ciprofloxacin
For patients with gonorrhea, detection of the wild-type serine 91 genotype of the gyrA gene of Neisseria gonorrhoeae is predictive of a successful treatment outcome with ciprofloxacin.
HPV Prevalence Higher in Adults With More Than 5 Lifetime Sexual Partners
Clinicians must consider patient sexual history in the decision-making process for adult HPV vaccination.
Teen HPV Vaccination Rates Suboptimal
Lack of parental intent to initiate and complete the human papillomavirus (HPV) vaccine series for adolescents is a major public health concern.
Epidemiology of Herpes Simplex Virus in Europe Transitioning
The epidemiology of herpes simplex virus (HSV)-1 is transitioning away from oral acquisition in childhood with an increasing proportion of HSV-1 detection in genital herpes.
American Cancer Society Updates HPV Vaccination Guidelines
The American Cancer Society has updated guidelines on human papillomavirus (HPV) vaccination, emphasizing that vaccination should be routinely offered at age 9 to 12 years.
Gardasil 9 Approved to Prevent Certain HPV-Related Head and Neck Cancers
The FDA has approved an expanded indication for Gardasil 9® (human papillomavirus 9-valent vaccine [HPV], recombinant; Merck) to include the prevention of oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58 in patients aged 9 to 45 years.
- Loading...
Loading...
Next post in Genitourinary
Loading... 
Loading...